Quantbot Technologies LP Has $35,000 Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Quantbot Technologies LP trimmed its position in shares of Bausch Health Companies Inc. (NYSE:BHC) by 95.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,352 shares of the company’s stock after selling 97,191 shares during the quarter. Quantbot Technologies LP’s holdings in Bausch Health Companies were worth $35,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in Bausch Health Companies by 3.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,269,478 shares of the company’s stock valued at $10,373,000 after acquiring an additional 42,539 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of Bausch Health Companies by 14.4% in the third quarter. Cerity Partners LLC now owns 79,290 shares of the company’s stock valued at $647,000 after purchasing an additional 9,978 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Bausch Health Companies by 26.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,807 shares of the company’s stock worth $628,000 after purchasing an additional 16,101 shares in the last quarter. Verition Fund Management LLC acquired a new position in Bausch Health Companies during the third quarter worth $808,000. Finally, Cinctive Capital Management LP grew its position in Bausch Health Companies by 25.9% in the third quarter. Cinctive Capital Management LP now owns 83,710 shares of the company’s stock valued at $683,000 after purchasing an additional 17,233 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Trading Down 3.2 %

Shares of BHC opened at $6.27 on Wednesday. The stock has a market capitalization of $2.31 billion, a PE ratio of -52.20, a P/E/G ratio of 0.37 and a beta of 0.59. The firm’s 50 day moving average is $7.03 and its 200-day moving average is $7.73. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $11.46.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Equities research analysts predict that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Jefferies Financial Group reissued a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada dropped their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.